Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.4360
-0.0150 (-3.33%)
At close: Mar 31, 2025, 4:00 PM
0.4391
+0.0031 (0.71%)
After-hours: Mar 31, 2025, 7:56 PM EDT
Cosmos Health Revenue
Cosmos Health had revenue of $12.41M in the quarter ending September 30, 2024, a decrease of -3.22%. This brings the company's revenue in the last twelve months to $56.04M, up 13.01% year-over-year. In the year 2023, Cosmos Health had annual revenue of $53.38M with 6.02% growth.
Revenue (ttm)
$56.04M
Revenue Growth
+13.01%
P/S Ratio
0.13
Revenue / Employee
$455,627
Employees
123
Market Cap
9.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
| Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
| Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
| Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
| Dec 31, 2019 | 39.68M | 2.59M | 6.99% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
COSM News
- 4 weeks ago - Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates - Accesswire
- 5 weeks ago - Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1 - Accesswire
- 6 weeks ago - Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market - Accesswire
- 7 weeks ago - Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market - Accesswire
- 7 weeks ago - Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations - Accesswire
- 7 weeks ago - Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility - Accesswire
- 7 weeks ago - Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar - Accesswire
- 7 weeks ago - Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market - Accesswire